Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19

Aditya Sahai; Rohan Bhandari; Matthew Godwin; Thomas McIntyre; Mina K. Chung; Jean Pierre Iskandar; Hayaan Kamran; Essa Hariri; Anu Aggarwal; Robert Burton; Ankur Kalra; John R. Bartholomew; Keith R. McCrae; Ayman Elbadawi; James Bena; Lars G. Svensson; Samir Kapadia; Scott J. Cameron

doi:10.1177/1358863X211012754

Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19

Aditya Sahai
, Rohan Bhandari
, Matthew Godwin
, Thomas McIntyre
, Mina K. Chung
, Jean Pierre Iskandar
, Hayaan Kamran
, Essa Hariri
, Anu Aggarwal
, Robert Burton
, Ankur Kalra
, John R. Bartholomew
, Keith R. McCrae
, Ayman Elbadawi
, James Bena
, Lars G. Svensson
, Samir Kapadia
, Scott J. Cameron

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appear distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.

Original language	English (US)
Pages (from-to)	626-632
Number of pages	7
Journal	Vascular Medicine
Volume	26
Issue number	6
DOIs	https://doi.org/10.1177/1358863X211012754
State	Published - Dec 2021

Keywords

ACE2
COVID-19
platelets
SARS-CoV-2
thrombosis
TMPRSS2

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1177/1358863X211012754

Cite this

Sahai, A., Bhandari, R., Godwin, M., McIntyre, T., Chung, M. K., Iskandar, J. P., Kamran, H., Hariri, E., Aggarwal, A., Burton, R., Kalra, A., Bartholomew, J. R., McCrae, K. R., Elbadawi, A., Bena, J., Svensson, L. G., Kapadia, S., & Cameron, S. J. (2021). Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vascular Medicine, 26(6), 626-632. https://doi.org/10.1177/1358863X211012754

Sahai, A, Bhandari, R, Godwin, M, McIntyre, T, Chung, MK, Iskandar, JP, Kamran, H, Hariri, E, Aggarwal, A, Burton, R, Kalra, A, Bartholomew, JR, McCrae, KR, Elbadawi, A, Bena, J, Svensson, LG, Kapadia, S & Cameron, SJ 2021, 'Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19', Vascular Medicine, vol. 26, no. 6, pp. 626-632. https://doi.org/10.1177/1358863X211012754

@article{3b6ca5f9ce7d4273978a8a79fd165b54,

title = "Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19",

abstract = "Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appear distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.",

keywords = "ACE2, COVID-19, platelets, SARS-CoV-2, thrombosis, TMPRSS2",

author = "Aditya Sahai and Rohan Bhandari and Matthew Godwin and Thomas McIntyre and Chung, \{Mina K.\} and Iskandar, \{Jean Pierre\} and Hayaan Kamran and Essa Hariri and Anu Aggarwal and Robert Burton and Ankur Kalra and Bartholomew, \{John R.\} and McCrae, \{Keith R.\} and Ayman Elbadawi and James Bena and Svensson, \{Lars G.\} and Samir Kapadia and Cameron, \{Scott J.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2021.",

year = "2021",

month = dec,

doi = "10.1177/1358863X211012754",

language = "English (US)",

volume = "26",

pages = "626--632",

journal = "Vascular Medicine",

issn = "1358-863X",

publisher = "SAGE Publications Ltd",

number = "6",

}

TY - JOUR

T1 - Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19

AU - Sahai, Aditya

AU - Bhandari, Rohan

AU - Godwin, Matthew

AU - McIntyre, Thomas

AU - Chung, Mina K.

AU - Iskandar, Jean Pierre

AU - Kamran, Hayaan

AU - Hariri, Essa

AU - Aggarwal, Anu

AU - Burton, Robert

AU - Kalra, Ankur

AU - Bartholomew, John R.

AU - McCrae, Keith R.

AU - Elbadawi, Ayman

AU - Bena, James

AU - Svensson, Lars G.

AU - Kapadia, Samir

AU - Cameron, Scott J.

PY - 2021/12

Y1 - 2021/12

N2 - Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appear distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.

AB - Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appear distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.

KW - ACE2

KW - COVID-19

KW - platelets

KW - SARS-CoV-2

KW - thrombosis

KW - TMPRSS2

UR - https://www.scopus.com/pages/publications/85106332589

UR - https://www.scopus.com/pages/publications/85106332589#tab=citedBy

U2 - 10.1177/1358863X211012754

DO - 10.1177/1358863X211012754

M3 - Article

C2 - 34010070

AN - SCOPUS:85106332589

SN - 1358-863X

VL - 26

SP - 626

EP - 632

JO - Vascular Medicine

JF - Vascular Medicine

IS - 6

ER -

Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this